Precision oncology: Charting a path forward to broader deployment of genomic profiling

PLoS Medicine

Volumn 14, Issue 2, 2017, Pages

  Schram, Alison M ^a   Berger, Michael F ^a,b   Hyman, David M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES AND PROTEINS; TRASTUZUMAB; TROPOMYOSIN RECEPTOR KINASE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; GENE MUTATION; GENOMICS; HUMAN; IMMUNOTHERAPY; NEXT GENERATION SEQUENCING; ONCOLOGY; PERSONALIZED MEDICINE; TREATMENT OUTCOME; GENE EXPRESSION PROFILING; MOLECULARLY TARGETED THERAPY; PROCEDURES; TRENDS;

GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE;

EID: 85014497847     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002242     Document Type: Article

References (15)

1. Shendure J, Ji H, Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–45. doi: 10.1038/nbt148618846087
2. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31. doi: 10.1038/nbt.269624142049
3. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17:251–64. doi: 10.1016/j.jmoldx.2014.12.00625801821
4. Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol. 2016;2:104–11. doi: 10.1001/jamaoncol.2015.520826556299
5. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinforma Oxf Engl. 2014;30:1015–16.
6. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC, Microsatellite instability detection by next generation sequencing. Clin Chem. 2014;60:1192–99. doi: 10.1373/clinchem.2014.22367724987110
7. de Bono JS, Ashworth A, Translating cancer research into targeted therapeutics. Nature. 2010;467:543–49. doi: 10.1038/nature0933920882008
8. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015;33:2753–62. doi: 10.1200/JCO.2014.60.416526014291
9. Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, et al. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. J Oncol Pract Am Soc Clin Oncol. 2016;12:e396–404.
10. NCI-MATCH / EAY131 Interim Analysis. In: ECOG-ACRIN [cited 17 Sep 2016]. http://ecog-acrin.org/nci-match-eay131/interim-analysis
11. Amatu A, Sartore-Bianchi A, Siena S, NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023. doi: 10.1136/esmoopen-2015-00002327843590
12. Hong DS, Farago AF, Brose MS, Burris HA, Dowlati A, Bauer TM, et al. Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT008.
13. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:1683–96. doi: 10.1016/S1470-2045(16)30392-827836716
14. Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016;22:464–71. doi: 10.1038/nm.408927149219
15. Peguero JA, Knost JA, Bauer TM, Taylor MH, Braiteh FS, Eder JP, et al. Successful implementation of a novel trial model: The Signature program [abstract]. J Clin Oncol. 2015;33 (suppl; abstr 106)